Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to TAF Monotherapy in Multidrug-Resistant Chronic Hepatitis B with Prior NUCs Combination Therapy
ChiCTR2300068651Phase 4Not yet recruiting
- Sponsor
- The Third Hospital of Hebei Medical University
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tenofovir alafenamide in Chronic Hepatitis B (CHB), sponsored by The Third Hospital of Hebei Medical University. Primary endpoint: HBV-DNA. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2300068651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068651.